project id: TCGA-PRAD; case submitter id: TCGA-J9-A52C; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.84; age at index: 57; days to birth: -20966; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1955; age at diagnosis: 20966; ajcc clinical t: T1c; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 178.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; days to collection: 156; initial weight: 90.0; oct embedded: false; preservation method: Unknown; sample id: f7d1a942-2afa-4aec-b70a-4eeecddb5b7d; sample submitter id: TCGA-J9-A52C-01A; portion id: fdbdaa37-c270-45fa-8c5a-4b2dec570415; portion submitter id: TCGA-J9-A52C-01A-11; slide id: a622f816-3814-439c-8638-7466c694e61f; slide submitter id: TCGA-J9-A52C-01A-01-TS1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 20.0; percent stromal cells: 0.0; percent tumor cells: 80.0; percent tumor nuclei: 75.0; section location: TOP;